Navigation Links
Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009
Date:3/9/2009

SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced its fourth quarter and full year financial results for 2008 and will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. EDT (1:30 p.m. PDT) on March 10, 2009. Interested investors may participate in the conference call by dialing 877-719-9791 (US) or +1-719-325-4828 (international). Participants may also access both the live and archived webcast of the conference call, which will be available for at least 10 business days following the call, from the homepage and the investor relations section of Nile's website at www.nilethera.com.

Year-end Summary

During 2008, Nile made important progress in the clinical development of CD-NP for the treatment of patients with acute heart failure. Nile executed a focused clinical development plan for CD-NP, which included starting and completing a Phase 1b study to establish the maximum tolerated dose (MTD) and to assess the pharmacologic effects of CD-NP on blood pressure and renal function in stable heart failure patients, and also starting and completing a Phase 2a study to assess hemodynamic and renal effects of CD-NP in acute heart failure patients. Nile believes that the results of these studies indicate:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min in stable and acute heart failure patients;
  • CD-NP blood pressure effects were dose-dependent and well characterized in chronic heart failure patients;
  • In the anticipated therapeutic dose range, CD-NP produced a statistically
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics Shareholders Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
2. Cell Therapeutics Announces Receipt of NASDAQ Listing Update
3. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
4. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
5. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
6. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... world,s first commercially achieved F.O.G. (fats, oils, grease) wastewater treatment ... Laguna Beach. , ... San Marcos, ... Reduction Systems, Inc __title__ Green Technology for the Hospitality Industry] ...
... Aug. 6 deCODE genetics,(Nasdaq: DCGN ) ... ended June 30, 2008. A conference call to ... be webcast live tomorrow,Thursday, August 7, at 8:00am ... Operating loss for the second quarter 2008 was ...
... California venture will use personalized stem cell technology to battle ... ... VIEW, Calif., Aug. 6 iZumi Bio, Inc.,announced today that John ... Stem Cells Generated from Patients with,ALS Can Be Differentiated into Motor ...
Cached Biology Technology:Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 2Grease Reduction System a Break Through in Truly "Green" Technology for Luxury Resort 3deCODE genetics Announces Second Quarter 2008 Financial Results 2deCODE genetics Announces Second Quarter 2008 Financial Results 3deCODE genetics Announces Second Quarter 2008 Financial Results 4deCODE genetics Announces Second Quarter 2008 Financial Results 5deCODE genetics Announces Second Quarter 2008 Financial Results 6deCODE genetics Announces Second Quarter 2008 Financial Results 7deCODE genetics Announces Second Quarter 2008 Financial Results 8deCODE genetics Announces Second Quarter 2008 Financial Results 9iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits 2
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
... The RapidStak is a fast and ... class. Its high capacity and ... more confident walk away time than ... ease of set-up make for a ...
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use. This advanced microplate washer meets the exacting standards of today's assay requirements....
Biology Products: